DreaMed Diabetics attained CE Mark for Platform tackling Type 1 diabetes

DreaMed Diabetes asserted that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.

DreaMed Diabetes’ cloud-based solution achieved similar glycemic control to that of medical experts in pilot studies, while simplifying patient experience, by offering a personalized insulin treatment plan based on the analysis of vast amounts of data from a variety of sources. Advisor Pro uses proprietary algorithms combining event-driven, machine learning and fuzzy logic technologies to process data from a range of connected devices, including insulin pumps, continuous glucose monitors or self-management blood glucometers, and food consumption information. The data is then analyzed to provide an informed and optimized insulin dosing treatment plan for maintaining balanced glucose levels.

Prof. Thomas Danne of Auf der Bult Hospital for Children and Adolescents, Hannover, Germany stated, “Nowadays, managing diabetes has become more complicated, especially due to continuous glucose sensors that offer frequent readings and more accurate information on the glucose levels of our patients. Not all care providers have the expertise or time to frequently analyze the vast amount of diabetes data available for deciding on optimized treatment, which has shown to be fundamental for maintaining sufficient glucose control. DreaMed’s solution offers healthcare providers a simple, reliable, automated, cloud-based decision-support tool.”

 

 

Comments (0)
Add Comment